Reading again over the article below and I think we can gain something of an understanding for the revenue model that will be used
It offers residential aged care staff looking after people with dementia a simple reproducible means of assessing and monitoring pain, he said.
“This should result in better pain management and a reduction in pain related behavioural problems, in turn decreasing the need for psychotropic medications.”
CEO of ePAT Technologies, Philip Daffas said the regulatory approval meant the app would be available in Australia in the final quarter of 2017.
“Our commercial model will be based on a subscription model that fits with the needs of the enterprise market, such as the carers in aged care facilities and carers for home use,” Mr Dafas said.
From the info above I would assume that Daffas intends to justify the apps monthly fee based on the savings that will be seen by reducing the care and medication costs of antipsychotic meds.
The article below is well worth a read to gain further understanding on the costs associated with treatments.
